Thanks Chiugray,
If you're right about this, and it makes sense to me, if we have the capacity in numbers of EDEN units we can deploy, it will take practically no time before DCVax-L is being utilized by virtually millions of patients annually.
With a compendium listing permitting Doctors to utilize the vaccine with virtually all of the deadliest solid cancers word of improved efficacy will grow far faster than from trials which take years to reveal data. I suspect they'll want to do the trials to eventually gain expanded labels unless provisions already exist to change labels based on a massive amount of anecdotal evidence. I don't know if such possibilities exist, but frankly they should.
I've always believed that the regulators, all of them, should be able to react to what's right in front of their eyes. It shouldn't take millions of sheets of paper to prove to them what's directly in front of them.
Frankly I've had my doubts about how the incoming Administration will handle healthcare, but perhaps it could bring major improvements if those judging new products are permitted to get into what's being seen and not wait for applications that require a million or more pages and take years to prepare.
Who knows, perhaps even the right to try will become what it was intended to be with the change of Administrations.
Gary
Bullish
Market Data 
Markets 
AI
